Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adaptive platform trial of antithrombotic strategies in hospitalized adults with COVID-19
2020-004285-19Phase 4Suspended
- Sponsor
- FIBHULP
- Start
- Sep 2020
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of enoxaparin, dalteparin, fondaparinux, heparin and tinzaparin in coronavirus disease 2019 (COVID-19) (5 arms), sponsored by FIBHULP. Primary endpoint: 21 Day Organ Support Free Days. Started Sep 2020; status: suspended.
02
Drugs
enoxaparindalteparinfondaparinuxheparintinzaparin
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-004285-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004285-19.